Literature DB >> 22678952

Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.

Nadia Bahi-Buisson1, Nathalie Villeneuve, Emilie Caietta, Aurélia Jacquette, Helene Maurey, Gert Matthijs, Hilde Van Esch, Andrée Delahaye, Anne Moncla, Mathieu Milh, Flore Zufferey, Bertrand Diebold, Thierry Bienvenu.   

Abstract

Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in epileptic encephalopathies in females with infantile spasms with features that overlap with Rett syndrome. With more than 80 reported patients, the phenotype of CDKL5-related encephalopathy is well-defined. The main features consist of seizures starting before 6 months of age, severe intellectual disability with absent speech and hand stereotypies and deceleration of head growth, which resembles Rett syndrome. However, some clinical discrepancies suggested the influence of genetics and/or environmental factors. No genotype-phenotype correlation has been defined and thus there is a need to examine individual mutations. In this study, we analyzed eight recurrent CDKL5 mutations to test whether the clinical phenotype of patients with the same mutation is similar and whether patients with specific CDKL5 mutations have a milder phenotype than those with other CDKL5 mutations. Patients bearing missense mutations in the ATP binding site such as the p.Ala40Val mutation typically walked unaided, had normocephaly, better hand use ability, and less frequent refractory epilepsy when compared to girls with other CDKL5 mutations. In contrast, patients with mutations in the kinase domain (such as p.Arg59X, p.Arg134X, p.Arg178Trp/Pro/Gln, or c.145 + 2T > C) and frameshift mutations in the C-terminal region (such as c.2635_2636delCT) had a more severe phenotype with infantile spasms, refractory epileptic encephalopathy, absolute microcephaly, and inability to walk. It is important for clinicians to have this information when such patients are diagnosed.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678952     DOI: 10.1002/ajmg.a.35401

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  23 in total

Review 1.  The genetics of the epilepsies.

Authors:  Christelle M El Achkar; Heather E Olson; Annapurna Poduri; Phillip L Pearl
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 2.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

Authors:  Heather E Olson; Scott T Demarest; Elia M Pestana-Knight; Lindsay C Swanson; Sumaiya Iqbal; Dennis Lal; Helen Leonard; J Helen Cross; Orrin Devinsky; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-02-23       Impact factor: 3.372

Review 3.  Severity Assessment in CDKL5 Deficiency Disorder.

Authors:  Scott Demarest; Elia M Pestana-Knight; Heather E Olson; Jenny Downs; Eric D Marsh; Walter E Kaufmann; Carol-Anne Partridge; Helen Leonard; Femida Gwadry-Sridhar; Katheryn Elibri Frame; J Helen Cross; Richard F M Chin; Sumit Parikh; Axel Panzer; Judith Weisenberg; Karen Utley; Amanda Jaksha; Sam Amin; Omar Khwaja; Orrin Devinsky; Jeffery L Neul; Alan K Percy; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-03-27       Impact factor: 3.372

4.  Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.

Authors:  Ailing Zhou; Song Han; Zhaolan Joe Zhou
Journal:  Front Biol (Beijing)       Date:  2017-01-23

5.  CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.

Authors:  Scott T Demarest; Heather E Olson; Angela Moss; Elia Pestana-Knight; Xiaoming Zhang; Sumit Parikh; Lindsay C Swanson; Katherine D Riley; Grace A Bazin; Katie Angione; Lisa-Marie Niestroj; Dennis Lal; Elizabeth Juarez-Colunga; Tim A Benke
Journal:  Epilepsia       Date:  2019-07-16       Impact factor: 5.864

6.  Novel mutations in cyclin-dependent kinase-like 5 (CDKL5) gene in Indian cases of Rett syndrome.

Authors:  Dhanjit Kumar Das; Bhakti Mehta; Shyla R Menon; Sarbani Raha; Vrajesh Udani
Journal:  Neuromolecular Med       Date:  2012-12-15       Impact factor: 3.843

Review 7.  The challenges and innovations for therapy in children with epilepsy.

Authors:  Jo M Wilmshurst; Anne T Berg; Lieven Lagae; Charles R Newton; J Helen Cross
Journal:  Nat Rev Neurol       Date:  2014-04-08       Impact factor: 42.937

8.  There is variability in the attainment of developmental milestones in the CDKL5 disorder.

Authors:  Stephanie Fehr; Helen Leonard; Gladys Ho; Simon Williams; Nick de Klerk; David Forbes; John Christodoulou; Jenny Downs
Journal:  J Neurodev Disord       Date:  2015-01-05       Impact factor: 4.025

9.  Clinical features and gene mutational spectrum of CDKL5-related diseases in a cohort of Chinese patients.

Authors:  Ying Zhao; Xiaoying Zhang; Xinhua Bao; Qingping Zhang; Jingjing Zhang; Guangna Cao; Jie Zhang; Jiarui Li; Liping Wei; Hong Pan; Xiru Wu
Journal:  BMC Med Genet       Date:  2014-02-25       Impact factor: 2.103

10.  Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling.

Authors:  Claudia Fuchs; Stefania Trazzi; Roberta Torricella; Rocchina Viggiano; Marianna De Franceschi; Elena Amendola; Cornelius Gross; Laura Calzà; Renata Bartesaghi; Elisabetta Ciani
Journal:  Neurobiol Dis       Date:  2014-06-18       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.